REGIMENS
First-Line Targeted Therapies
Sunitinib (Sutent) Sunitinib 50mg/day orally for 4 weeks on, and 2 weeks off. Bevacizumab (Avastin) + interferon-α-2a (IFN-α-2a)1,4–6 Bevacizumab 10mg/kg IV every 2 weeks plus IFN-α-2a 9 million IU SQ three times a week.
Pazopanib (Votrient) Pazopanib 800mg orally once daily.
Temsirolimus (Torisel) Temsirolimus 25mg IV once weekly administered over 30–60 min.
Second-Line Targeted Therapy After Treatment Failure
Everolimus (Afinitor) following tyrosine kinase inhibitor1,11,12 Everolimus 10mg orally once daily.
Axitinib (Inlyta) Axitinib 5mg orally every 12 hrs; may increase to 7mg every 12 hrs after 2 weeks based on criteria; may increase to 10mg every 12 hrs after 2 weeks based on criteria.
Sorafenib (Nexavar) following cytokine therapy Sorafenib 400mg orally twice daily. Sunitinib following cytokine therapy1–3 Sunitinib 50mg/day orally for 4 weeks on, and 2 weeks off.
Pazopanib following cytokine therapy1,4,7,8 Pazopanib 800mg orally once daily.
Additional agents include cabozantinib, lenvantinib, and pembrolizumab.